StreetInsider.com News Articles

ArriVent BioPharma (AVBP) PT Raised to $27 at Jefferies

Fri, 16 Oct 2026 06:07:02 -0400

Jefferies analyst Kelly Shi raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $27.00 (from $18.00) while maintaining a Buy rating.

Form SCHEDULE 13G ArriVent BioPharma, Inc. Filed by: Vivo Opportunity Fund Holdings, L.P.

Tue, 13 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27181019.html

Form 8-K ArriVent BioPharma, Inc. For: Oct 12

Tue, 13 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261013/27176322.html

ArriVent doses first patient in Phase 1 trial of ADC ARR-002

Mon, 12 Oct 2026 16:03:04 -0400

ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that the first patient has been dosed in a Phase 1 clinical trial in the U.S. with ARR-002, a dual-target antibody-drug conjugate (ADC) being studied for ovarian and endometrial cancer.

ARR-002 is described by the company as a potential first-in-class MUC16/NaPi2b dual-target tetravalent ADC. The trial, registered as NCT07755436, is designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of ARR-002 in patients with advanced or metastatic ovarian or endometrial cancer.

Stuart Lutzker, MD, Ph.D., President of Research and Development at ArriVent, said the dual-targeting approach of ARR-002 "is designed to overcome a key limitation of

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

Mon, 12 Oct 2026 16:01:00 -0400

NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate (ADC) for ovarian and endometrial cancer.

“We are pleased to have dosed our first patient with ARR-002, our second ADC from our portfolio to enter the clinic,” said Stuart Lutzker, MD, Ph.D., President of

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

Mon, 12 Oct 2026 16:01:00 -0400

“We are pleased to have dosed our first patient with ARR-002, our second ADC from our portfolio to enter the clinic,” said Stuart Lutzker, MD, Ph.D., President of

Form SCHEDULE 13D/A ArriVent BioPharma, Inc. Filed by: ORBIMED ADVISORS LLC

Thu, 08 Oct 2026 18:40:00 -0400

si-local-file:///var/storage/secattach/20261008/27167928.html

ArriVent BioPharma (AVBP) PT Lowered to $27 at H.C. Wainwright

Thu, 08 Oct 2026 07:10:28 -0400

(Updated - October 8, 2026 7:10 AM EDT)

H.C. Wainwright analyst Robert Burns lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $27.00 (from $47.00) while maintaining a Buy rating.

The analyst commented: "FURVENT trial narrowly misses PFS primary endpoint. Earlier this week, ArriVent announced that the Phase 3 FURVENT trial (NCT05607550), which compared firmonertinib against platinum-based chemo + pemetrexed in 1L EGFR ex20ins+ NSCLC patients, failed to meet its PFS primary endpoint because the control arm outperformed; recall, FURVENT was powered to detect a three-month mPFS difference between firmonertinib and the control arm, with the expectation that firmonertinib and the

ArriVent BioPharma (AVBP) PT Lowered to $27 at H.C. Wainwright

Thu, 08 Oct 2026 07:10:28 -0400

(Updated - October 8, 2026 7:10 AM EDT)

H.C. Wainwright analyst Robert Burns lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $27.00 (from $47.00) while maintaining a Buy rating.

ArriVent BioPharma (AVBP) PT Lowered to $18 at Guggenheim

Wed, 07 Oct 2026 07:33:53 -0400

Guggenheim analyst Michael Schmidt lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $18.00 (from $45.00) while maintaining a Buy rating.

ArriVent BioPharma (AVBP) PT Lowered to $18 at Truist Securities

Wed, 07 Oct 2026 07:13:11 -0400

Truist Securities analyst Supawat Thongthip lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $18.00 (from $45.00) while maintaining a Buy rating.

ArriVent BioPharma (AVBP) PT Lowered to $29 at BTIG

Wed, 07 Oct 2026 05:03:16 -0400

BTIG analyst Jeet Mukherjee lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $29.00 (from $42.00) while maintaining a Buy rating.

The analyst comments "We were ultimately mistaken on our call for FURVENT, having not fully accounted for the difference between investigator vs. BICR PFS reads that drove chemo arm outperformance in this trial. With FURVENT in the rearview now, our discussions with investors revolve around the stock at a new entry point and the upcoming ARR-217/CDH17 data at ESMO. We anticipate a ~20% ORR across doses and ~25% ORR at potential go forward doses in mCRC would be perceived

ArriVent BioPharma (AVBP) PT Lowered to $29 at BTIG

Wed, 07 Oct 2026 05:03:16 -0400

BTIG analyst Jeet Mukherjee lowered the price target on ArriVent BioPharma (NASDAQ: AVBP) to $29.00 (from $42.00) while maintaining a Buy rating.

ArriVent stock tumbles 60% after trial misses primary endpoint

Tue, 06 Oct 2026 08:45:36 -0400

Investing.com -- ArriVent BioPharma (NASDAQ:AVBP) shares fell 63% Tuesday after the company announced its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer failed to meet its primary endpoint.

The trial, which evaluated firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous NSCLC harboring EGFR exon 20 insertion mutations, did not achieve its primary endpoint of progression free survival by blinded independent central review. The study compared firmonertinib at 160 mg and 240 mg doses against platinum-based chemotherapy with pemetrexed.

According to the results, median PFS by BICR was 11.0

Form 8-K ArriVent BioPharma, Inc. For: Oct 06

Tue, 06 Oct 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20261006/27152311.html

ArriVent's firmonertinib fails primary endpoint in phase 3 lung cancer trial

Tue, 06 Oct 2026 08:01:01 -0400

ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that its Phase 3 FURVENT trial evaluating firmonertinib monotherapy in previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR).

By BICR, the 240mg dose of firmonertinib showed a median PFS of 11.0 months compared to 9.5 months for the chemotherapy control arm, with a hazard ratio of 0.75 and a p-value of 0.0654, falling short of statistical significance. The 160mg dose showed a median PFS of 8.4 months.

By investigator assessment,

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

Tue, 06 Oct 2026 08:00:00 -0400

NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review (BICR). Clinical benefit was observed with secondary endpoints such as PFS by investigator’s assessment and confirmed objective response

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

Tue, 06 Oct 2026 08:00:00 -0400

ArriVent BioPharma (AVBP) Reiterated at Overweight by Cantor Fitzgerald

Tue, 22 Sep 2026 07:45:29 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on ArriVent BioPharma (NASDAQ: AVBP).

The analyst commented, "The first presentation of CDH17 ADC, ARR-217, data will disclose safety and preliminary efficacy data from the Phase 1 doseescalation. Competitor data from Multitude's (pvt.) and CytomX's (CTMX, OW, Olivia) ADCs in colorectal cancer set the benchmark ORR at ~20-30%. An acceptable safety profile, especially on diarrhea rate, could be key for potential combinations for earlier lines of therapy."

For an analyst ratings summary and ratings history on ArriVent BioPharma click here. For more ratings news on ArriVent BioPharma click here.

Shares of ArriVent

ArriVent BioPharma (AVBP) PT Raised to $47 at H.C. Wainwright

Mon, 17 Aug 2026 06:49:29 -0400

(Updated - August 17, 2026 6:49 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $47.00 (from $44.00) while maintaining a Buy rating.

The analyst commented: "The next key potential value inflection point for ArriVent is the expected top-line data readout in 2H26 from the Phase 3 FURVENT trial (NCT05607550), which is comparing firmonertinib against platinum-based chemo + pemetrexed in 1L EGFR ex20ins+ NSCLC patients. Per management, FURVENT is powered to detect a three-month mPFS difference between firmonertinib and the control arm, with the expectation that firmonertinib and the control arm will achieve an

ArriVent BioPharma (AVBP) PT Raised to $47 at H.C. Wainwright

Mon, 17 Aug 2026 06:49:29 -0400

(Updated - August 17, 2026 6:49 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $47.00 (from $44.00) while maintaining a Buy rating.

Citi cuts ArriVent BioPharma price target to $40

Thu, 13 Aug 2026 06:12:47 -0400

Citi analyst Yigal Nochomovitz lowered his price target on ArriVent BioPharma (NASDAQ: AVBP) to $40 from $43, while maintaining a Buy rating, according to a research note.

The revision follows ArriVent's updated timeline for its global Phase 3 FURVENT study in first-line exon 20, which is now expected to read out in the second half of 2026, compared to a prior estimate of mid-2026. This marks the second time the company has pushed out the FURVENT progression-free survival readout, with the first delay occurring in March 2026.

The analyst noted that management remains blinded to the data, but external trial monitors indicated

ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c

Wed, 12 Aug 2026 17:24:51 -0400

ArriVent BioPharma, Inc. (NASDAQ: AVBP) reported Q2 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92).

For earnings history and earnings-related data on ArriVent BioPharma, Inc. (AVBP) click here.

Form 10-Q ArriVent BioPharma, Inc. For: Jun 30

Wed, 12 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260812/26913252.html

Form 10-Q ArriVent BioPharma, Inc. For: Jun 30

Wed, 12 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260812/26913252.html